Back to top
more

Exscientia (EXAI)

(Real Time Quote from BATS)

$5.11 USD

5.11
407,030

-0.02 (-0.39%)

Updated May 17, 2024 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Brian Bolan headshot

Brian's Big Idea on Healthcare

by Brian Bolan

Big moving drug stocks and the HealthCare Innovators service at Zacks.

Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 67.8% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.

Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 68.03%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 68% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Is Dynavax Technologies (DVAX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Dynavax Technologies (DVAX) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.

Wall Street Analysts Believe Exscientia PLC Sponsored ADR (EXAI) Could Rally 76.12%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 76.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is a Surprise Coming for Exscientia (EXAI) This Earnings Season?

by Zacks Equity Research

Exscientia (EXAI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Waters (WAT) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Waters' (WAT) Q3 results benefit from a strong Pharmaceutical market, as well as a strong contribution from the Wyatt acquisition.

Does Exscientia PLC Sponsored ADR (EXAI) Have the Potential to Rally 104.18% as Wall Street Analysts Expect?

by Zacks Equity Research

The mean of analysts' price targets for Exscientia PLC Sponsored ADR (EXAI) points to a 104.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

New Strong Buy Stocks for October 25th

by Zacks Equity Research

RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023.

Wall Street Analysts Predict a 99.07% Upside in Exscientia PLC Sponsored ADR (EXAI): Here's What You Should Know

by Zacks Equity Research

The consensus price target hints at a 99.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?

by Zacks Equity Research

Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Down -33.28% in 4 Weeks, Here's Why Exscientia PLC Sponsored ADR (EXAI) Looks Ripe for a Turnaround

by Zacks Equity Research

Exscientia PLC Sponsored ADR (EXAI) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -10.61% and 1.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.

OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Oncternal Therapeutics (ONCT) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 12.50% and 11.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 62.6% in Exscientia PLC Sponsored ADR (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J

by Zacks Equity Research

Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.

Exscientia PLC Sponsored ADR (EXAI) Upgraded to Buy: Here's Why

by Zacks Equity Research

Exscientia PLC Sponsored ADR (EXAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Esperion (ESPR) Q1 Earnings Beat on Robust Demand for Drugs

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports solid first-quarter results, beating estimates for earnings and sales. Cost-savings programs boost margins. Stock rallies.

Is Exscientia PLC Sponsored ADR (EXAI) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Exscientia PLC Sponsored ADR (EXAI) and Henry Schein (HSIC) have performed compared to their sector so far this year.

Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines

by Zacks Equity Research

Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform.